Mepolizumab in the treatment of eosinophilic esophagitis

Rana F. Ammoury, Sandeep Gupta

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Mepolizumab is a humanized monoclonal antibody that binds specifically to and inactivates a protein cell messenger termed IL-5, which plays a major role in the proliferation, maturation, activation and survival of eosinophils. As a result, mepolizumab has been studied in a number of eosinophil-associated diseases, such as asthma, hypereosinophilic syndrome and eosinophilic esophagitis (EE). EE is a clinical entity characterized by eosinophilic infiltration of the esophagus (≥15 eosinophils/high power field in one or more fields) in the absence of gastroesophageal reflux. EE is on the rise, and this can not be fully accounted for by increased recognition. Currently, available therapies, although successful in many cases, can be disappointing in some patients, whether from lack of response, negative impact on quality of life, or significant toxicity. In order to better define EE therapy, investigators are evaluating novel drugs, including anti-IL-5 agents such as mepolizumab. Mepolizumab has been demonstrated to significantly reduce mean blood and tissue eosinophil count. It is well-tolerated and no drug-related serious adverse events have been described in the published literature to date. Mepolizumab is currently under clinical investigation and is not yet available for general use.

Original languageEnglish
Pages (from-to)231-237
Number of pages7
JournalTherapy
Volume6
Issue number2
DOIs
StatePublished - Mar 2009

Fingerprint

Eosinophilic Esophagitis
Eosinophils
Interleukin-5
Hypereosinophilic Syndrome
Therapeutics
Antibodies, Monoclonal, Humanized
Gastroesophageal Reflux
Pharmaceutical Preparations
Esophagus
Asthma
Quality of Life
Research Personnel
mepolizumab
Proteins

Keywords

  • Anti-IL-5
  • Eosinophilic esophagitis
  • Mepolizumab

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Mepolizumab in the treatment of eosinophilic esophagitis. / Ammoury, Rana F.; Gupta, Sandeep.

In: Therapy, Vol. 6, No. 2, 03.2009, p. 231-237.

Research output: Contribution to journalArticle

Ammoury, Rana F. ; Gupta, Sandeep. / Mepolizumab in the treatment of eosinophilic esophagitis. In: Therapy. 2009 ; Vol. 6, No. 2. pp. 231-237.
@article{736466e5f48b48cca8c6b7d96e5cd3d0,
title = "Mepolizumab in the treatment of eosinophilic esophagitis",
abstract = "Mepolizumab is a humanized monoclonal antibody that binds specifically to and inactivates a protein cell messenger termed IL-5, which plays a major role in the proliferation, maturation, activation and survival of eosinophils. As a result, mepolizumab has been studied in a number of eosinophil-associated diseases, such as asthma, hypereosinophilic syndrome and eosinophilic esophagitis (EE). EE is a clinical entity characterized by eosinophilic infiltration of the esophagus (≥15 eosinophils/high power field in one or more fields) in the absence of gastroesophageal reflux. EE is on the rise, and this can not be fully accounted for by increased recognition. Currently, available therapies, although successful in many cases, can be disappointing in some patients, whether from lack of response, negative impact on quality of life, or significant toxicity. In order to better define EE therapy, investigators are evaluating novel drugs, including anti-IL-5 agents such as mepolizumab. Mepolizumab has been demonstrated to significantly reduce mean blood and tissue eosinophil count. It is well-tolerated and no drug-related serious adverse events have been described in the published literature to date. Mepolizumab is currently under clinical investigation and is not yet available for general use.",
keywords = "Anti-IL-5, Eosinophilic esophagitis, Mepolizumab",
author = "Ammoury, {Rana F.} and Sandeep Gupta",
year = "2009",
month = "3",
doi = "10.2217/14750708.6.2.231",
language = "English",
volume = "6",
pages = "231--237",
journal = "Therapy",
issn = "2044-9038",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Mepolizumab in the treatment of eosinophilic esophagitis

AU - Ammoury, Rana F.

AU - Gupta, Sandeep

PY - 2009/3

Y1 - 2009/3

N2 - Mepolizumab is a humanized monoclonal antibody that binds specifically to and inactivates a protein cell messenger termed IL-5, which plays a major role in the proliferation, maturation, activation and survival of eosinophils. As a result, mepolizumab has been studied in a number of eosinophil-associated diseases, such as asthma, hypereosinophilic syndrome and eosinophilic esophagitis (EE). EE is a clinical entity characterized by eosinophilic infiltration of the esophagus (≥15 eosinophils/high power field in one or more fields) in the absence of gastroesophageal reflux. EE is on the rise, and this can not be fully accounted for by increased recognition. Currently, available therapies, although successful in many cases, can be disappointing in some patients, whether from lack of response, negative impact on quality of life, or significant toxicity. In order to better define EE therapy, investigators are evaluating novel drugs, including anti-IL-5 agents such as mepolizumab. Mepolizumab has been demonstrated to significantly reduce mean blood and tissue eosinophil count. It is well-tolerated and no drug-related serious adverse events have been described in the published literature to date. Mepolizumab is currently under clinical investigation and is not yet available for general use.

AB - Mepolizumab is a humanized monoclonal antibody that binds specifically to and inactivates a protein cell messenger termed IL-5, which plays a major role in the proliferation, maturation, activation and survival of eosinophils. As a result, mepolizumab has been studied in a number of eosinophil-associated diseases, such as asthma, hypereosinophilic syndrome and eosinophilic esophagitis (EE). EE is a clinical entity characterized by eosinophilic infiltration of the esophagus (≥15 eosinophils/high power field in one or more fields) in the absence of gastroesophageal reflux. EE is on the rise, and this can not be fully accounted for by increased recognition. Currently, available therapies, although successful in many cases, can be disappointing in some patients, whether from lack of response, negative impact on quality of life, or significant toxicity. In order to better define EE therapy, investigators are evaluating novel drugs, including anti-IL-5 agents such as mepolizumab. Mepolizumab has been demonstrated to significantly reduce mean blood and tissue eosinophil count. It is well-tolerated and no drug-related serious adverse events have been described in the published literature to date. Mepolizumab is currently under clinical investigation and is not yet available for general use.

KW - Anti-IL-5

KW - Eosinophilic esophagitis

KW - Mepolizumab

UR - http://www.scopus.com/inward/record.url?scp=69449106289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69449106289&partnerID=8YFLogxK

U2 - 10.2217/14750708.6.2.231

DO - 10.2217/14750708.6.2.231

M3 - Article

VL - 6

SP - 231

EP - 237

JO - Therapy

JF - Therapy

SN - 2044-9038

IS - 2

ER -